https://orcid.org/0000-0002-6622-8089
References
- Hanley DA, Adachi JD, Bell A, et al. Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 2012;66(12):1139–1146. doi: 10.1111/ijcp.12022
- European Medicines Agency. Prolia summary of product characteristics [Internet]. 2023 [cited 2023 Sep 26]. Available from: https://www.ema.europa.eu/en/documents/product-information/prolia-epar-product-information_en.pdf
- US Food and Drug Administration. Prolia prescribing information [Internet]. 2023 [cited 2023 Nov 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125320Orig1s211lbl.pdf
- Curtis EM, Reginster JY, Al-Daghri N, et al. Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clin Exp Res. 2022;34(4):695–714. doi: 10.1007/s40520-022-02100-4
- Kanis JA, Harvey NC, McCloskey E, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020;31(1):1–12. doi: 10.1007/s00198-019-05176-3
- Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2020 update. Endocr Pract. 2020;26(Suppl 1):1–46. doi: 10.4158/GL-2020-0524SUPPL
- Baumgart DC, Misery L, Naeyaert S, et al. Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front Pharmacol. 2019;10:279. doi: 10.3389/fphar.2019.00279
- Chen Q, Hu C, Liu Y, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose denosumab in healthy Chinese volunteers: a randomized, single-blind, placebo-controlled study. PLoS One. 2018;13(6):e0197984. doi: 10.1371/journal.pone.0197984
- An G. Concept of pharmacologic target-mediated drug disposition in large-molecule and small-molecule compounds. J Clin Pharmacol. 2020;60(2):149–163. doi: 10.1002/jcph.1545
- Gillett MJ, Vasikaran SD, Inderjeeth CA. The role of PINP in diagnosis and management of metabolic bone disease. Clin Biochem Rev. 2021;42(1):3–10.
- Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93(6):2149–2157. doi: 10.1210/jc.2007-2814
- Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25(1):72–81. doi: 10.1359/jbmr.090716
- Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007;22(12):1832–1841. doi: 10.1359/jbmr.070809
- Nakamura T, Matsumoto T, Sugimoto T, et al. Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab. 2014;99(7):2599–2607. doi: 10.1210/jc.2013-4175
- Pitale S, Thomas M, Rathi G, et al. A randomized placebo-controlled trial of the efficacy of denosumab in Indian postmenopausal women with osteoporosis. Indian J Endocrinol Metab. 2015;19(1):148–154. doi: 10.4103/2230-8210.146871
- US Food and Drug Administration. Immunogenicity testing of therapeutic protein products — developing and validating assays for anti-drug antibody detection [Internet]. 2019 [cited 2023 Sep 13]. Available from: https://www.fda.gov/media/119788/download
- European Medicines Agency. Xgeva summary of product characteristics [Internet]. 2022 [cited 2023 Sep 21]. Available from: https://www.ema.europa.eu/en/documents/product-information/xgeva-epar-product-information_en.pdf
- US Food and Drug Administration. Xgeva prescribing information [Internet]. 2020 [cited 2023 Sep 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125320s201lbl.pdf
- ClinicalTrials.gov. A phase 3 study to compare between CT-P41 and US-licensed prolia in postmenopausal women with osteoporosis [NCT04757376] [Internet]. 2023 [cited 2023 Sep 22]. Available from: https://www.clinicaltrials.gov/study/NCT04757376